| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| D647378-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $950.90 |
| Specifications & Purity | ≥96% |
|---|---|
| Biochemical and Physiological Mechanisms | DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways. |
| Storage Temp | Protected from light,Argon charged,Desiccated,Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways In Vitro DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus . DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson's disease symptom potentially and enhances neurotransmission. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (210–230 g) Dosage: 10 nmol/kg Administration: I.p. Result: Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. Animal Model: Adult male C57BL/6 mice (8 week-old) Dosage: 25 nmol/kg/day Administration: I.p. Result: Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). Animal Model: Adult male Sprague-Dawley (SD) rats (230-280 g) Dosage: 50 nmol/kg Administration: I.p. Result: Improved Parkinson's disease symptom potentially and enhanced neurotransmission. Form:Solid IC50& Target:GLP-1/GIP |
| Molecular Weight | 4875.49 |
|---|
Enter Lot Number to search for COA:
